Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT03449654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03449654
Other papers using this trial's data
  • Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial BMJ open diabetes research & care, 2021-09 DOI, PubMed 34518158, PMC8451300 In the PMC Open Access subset under CC BY-NC.
  • Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial Circulation. Cardiovascular imaging, 2021-07 DOI, PubMed 34187185, PMC8300846 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03449654. Randomized; double masking; primary purpose prevention. Start 2017-10-26 (actual); primary completion 2019-08-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
Acronym
LIRAFLAME
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Liraglutide
Intervention (Drug)
Placebo (for liraglutide)
Lead sponsor
Steno Diabetes Center Copenhagen (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)

Record details

Record id
cardio:ct-nct03449654
Content hash
1d4126bf830354f3301d126b644b115c623ebb64ec20e0a013df828967975aa2